Close

Business & Industry

EU-US Trade Deal Taking Shape as Pharma Tariffs Materialize

Finally, the Trump administration’s much-animated tariffs on pharmaceutical imports are now materializing in a new EU-US trade deal. However, there are still many questions that remain. As part of a trade agreement that was reached between the US and the...

AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D

AstraZeneca announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs...

Sino BioPharm to Acquire LaNova Medicines for $950.9 M Deal

LaNova Medicines, which happens to be a cancer drugmaker that previously licensed medicines to AstraZeneca as well as Merck & Co., has gone on to agree to get acquired by Sino BioPharmaceuticals in a deal worth almost $951 million. In...

Key Trends Shaping Indian Pharmaceutical Packaging Market

The pharmaceutical business has a major economic influence on both local and worldwide markets, and it is always changing according to different market trends. Packaging is essential to this industry. At the moment, the packaging guarantees patient safety by offering...

Regional Pharma Hubs for Effective Supply Chain Outcomes

It is well to be noted that the pharmaceutical sector has for long been characterized by its intricate, global supply chains designed in order to optimize production, decrease costs, and make sure that there is a timely delivery of...

tHIS ASEAN 2025: Transforming Healthcare in Southeast Asia

Kuala Lumpur, 9 June 2025 - tHIS ASEAN 2025 today opened its doors at the Kuala Lumpur Convention Centre with the biggest and most diverse group of the region's healthcare ecosystem. The three-day exhibition, held from 9-11 June 2025,...

Asia’s CROs VCs: Blurring Service Provider & Investor Roles

In a time characterized by accelerated innovation and ever-more complicated clinical environments, Asia is witnessing an invigorating shift in the role of Contract Research Organizations (CROs). Once seen as service organizations that assist in the pharmaceutical and biotech product...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »